CCND1 encodes cyclin D1, a cell-cycle regulator that partners with CDK4 and CDK6 to drive the transition from G1 to S phase, promoting cell growth, proliferation, and division. It helps control these processes by phosphorylating and inactivating the RB tumor suppressor, which in turn releases the E2F transcription program needed for cell-cycle entry. CCND1 is a well-established oncogene: its amplification or overexpression is common in many human cancers, including breast, lung, melanoma, and oral squamous cell carcinoma, where it allows cancer cells to proliferate independently of normal growth signals. Disruption of this gene's normal regulation is therefore frequently linked to cancer development and progression.

CCND1 drives cancer through amplification and overexpression of cyclin D1, so a Likely Benign result here means this single-codon in-frame deletion is not expected to disrupt the gene's cell-cycle regulatory function. Consistent with that, the variant has no predicted splice impact and falls in a repeat tract with no known function, giving no indication of the gain-of-function changes associated with CCND1-driven cancers.